Want to see IN:ZIMLAB full AI Analyst Report?
ZIMLAB Stock Chart & Stats
₹71.11
-₹1.76(-1.66%)
At close: 4:00 PM EST
₹71.11
-₹1.76(-1.66%)
Day’s Range― - ―
52-Week Range₹59.72 - ₹144.85
Previous CloseN/A
Volume52.11K
Average Volume (3M)7.92K
Market Cap
₹7.33B
Enterprise Value₹3.78K
Total Cash (Recent Filing)₹402.52M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)168.2
Beta1.03
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)0.82
Shares Outstanding53,658,490
10 Day Avg. Volume13,871
30 Day Avg. Volume7,921
Financial Highlights & Ratios
PEG Ratio-0.97
Price to Book (P/B)1.00
Price to Sales (P/S)0.80
P/FCF Ratio-39.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Dual Pharmaceutical Revenue ModelCombining own-brand and partnered manufacturing activities gives Zim Laboratories more than one route to market and monetization. This model can support customer reach, utilization of formulation capabilities, and recurring commercial relationships across domestic and export channels over the medium term.
Strengthening Equity BaseA rising equity base and moderate leverage provide financial support for ongoing pharmaceutical operations and investment. This comparatively steady balance sheet should give the company more flexibility than a highly indebted peer when funding products, capacity, or working-capital needs.
Positive Operating Cash FlowPositive operating cash flow indicates that the core business continues to generate cash from operations despite weaker reported earnings. That internal cash generation can help support routine funding needs and reduce reliance on external financing, even though investment outflows remain significant.
Bears Say
Sharp Earnings DeteriorationThe sharp decline in net income and operating profit signals weaker profitability and reduced earnings power. If this pressure persists, it could constrain internally funded growth, reduce returns on the company’s operating base, and make future performance more dependent on revenue recovery.
Volatile Negative Free Cash FlowRepeatedly volatile free cash flow weakens the quality and predictability of cash generation. The return to a negative figure means operating cash is not currently covering investment requirements, potentially limiting financial flexibility and increasing dependence on balance-sheet resources.
Inconsistent Revenue GrowthModest and uneven revenue growth suggests that demand expansion has not yet become a dependable trend. Inconsistent top-line performance makes it harder to absorb fixed costs, rebuild margins, and generate sustained operating leverage across the pharmaceutical portfolio.
Zim Laboratories Ltd. News
ZIMLAB FAQ
What was Zim Laboratories Ltd.’s price range in the past 12 months?
Zim Laboratories Ltd. lowest stock price was ₹59.72 and its highest was ₹144.85 in the past 12 months.
What is Zim Laboratories Ltd.’s market cap?
Zim Laboratories Ltd.’s market cap is ₹7.33B.
When is Zim Laboratories Ltd.’s upcoming earnings report date?
Zim Laboratories Ltd.’s upcoming earnings report date is Nov 09, 2026 which is in 52 days.
How were Zim Laboratories Ltd.’s earnings last quarter?
Zim Laboratories Ltd. released its earnings results on Aug 06, 2026. The company reported -₹0.75 earnings per share for the quarter.
Is Zim Laboratories Ltd. overvalued?
According to Wall Street analysts Zim Laboratories Ltd.’s price is currently Overvalued.
Does Zim Laboratories Ltd. pay dividends?
Zim Laboratories Ltd. pays a Annually dividend of ₹0.167 which represents an annual dividend yield of 0.15%. See more information on Zim Laboratories Ltd. dividends here
What is Zim Laboratories Ltd.’s EPS estimate?
Zim Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zim Laboratories Ltd. have?
Zim Laboratories Ltd. has 53,658,490 shares outstanding.
What happened to Zim Laboratories Ltd.’s price movement after its last earnings report?
Zim Laboratories Ltd. reported an EPS of -₹0.75 in its last earnings report. Following the earnings report the stock price went up 0.175%.
Which hedge fund is a major shareholder of Zim Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:ZIMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zim Laboratories Ltd.
Established in 1984 and based in Nagpur, India, ZIM Laboratories Limited is a pharmaceutical company that develops, produces, and supplies both finished drug formulations and pre-formulation ingredients. Operating domestically and internationally, ZIM specializes in providing technology-driven drug delivery solutions and exclusive, non-infringing manufacturing processes for generic pharmaceuticals. These offerings span semi-finished and finished product categories, encompassing forms like granules, pellets, taste-masked powders, suspensions, tablets, capsules, and oral thin films. Their extensive product range caters to various therapeutic areas, including urology, gastroenterology, cardiology, and anticoagulation, alongside antibiotics, anti-infectives, NSAIDs/pain management, and vitamins and supplements.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Kilitch Drugs (India) Limited
―
Medico Remedies Ltd.
―
Valiant Laboratories Ltd.
―